Colorectal Cancer Research Report 2023: Eight Major Market Drug Forecasts and Market Analysis 2021-2031

Dublin, Feb. 19, 2024 (GLOBE NEWSWIRE) -- The "Colorectal Cancer - Eight-Market Drug Forecast and Market Analysis" report has been added to * ResearchAndMarkets.com's* offering.

Despite being a rare blood cancer, CRC is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%.

Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). These sales forecasts leverage data on pharmaceutical sales and drug availability from the World Markets Healthcare (WMH) and POLI Price Intelligence databases.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for colorectal cancer (CRC). These sales forecasts leverage data on pharmaceutical sales and drug availability from the World Markets Healthcare (WMH) and POLI Price Intelligence databases.

In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the CRC treatment paradigm.

*Key Highlights*

· Report deliverables include a PowerPoint report and Excel-based forecast model
· Forecasts includes the 8MM
· Forecasts covers from 2021-2031
· Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031
· A moderate level of unmet need will remain for most colorectal cancer patient populations during the forecast period
· The late-stage pipeline in colorectal cancer is robust and is likely to provide significant clinical benefit to many colorectal cancer patient populations, with fierce competition expected

*Several markets across the 8MM will experience growth driven by common drivers -*

· Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs
· Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents
· Increased utilization of novel combination regimens with premium-priced agents

*Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries:*

· Patent expiry of Jakafi/Jakavi
· Patent expiry of Vonjo (pacritinib)
· Patent expiry of Inrebic (fedratinib)

*Scope*

· Overview of colorectal cancer, including epidemiology, symptoms, diagnosis, and disease management.
· Annualized colorectal cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
· Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the colorectal cancer therapeutics market.
· Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for colorectal cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
· Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

*Reasons to Buy*

· Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
· Develop business strategies by understanding the trends shaping and driving the global colorectal cancer therapeutics market.
· Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global colorectal cancer therapeutics market in the future.
· Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
· Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
· Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

*Key Topics Covered:*

*1 Colorectal Cancer: Executive Summary*
1.1 The colorectal cancer market will grow to $21.8B by 2031, at a compound annual growth rate of 3.3%
1.2 Combination therapies and immunotherapies for distinct segments are key R&D strategies in CRC
1.3 The level of unmet clinical need in colorectal cancer remains high during the forecast period, despite dramatic improvements by historical standards
1.4 The colorectal cancer pipeline is robust, with plenty of room for new market entrants
1.5 What do physicians think?

*2 Introduction*
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

*3 Disease Overview*
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Classification and staging systems

*4 Epidemiology*
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.5 Epidemiological forecast for CRC (2021-31)
4.5.1 Diagnosed incident cases of CRC
4.5.2 Age-specific diagnosed incident cases of CRC
4.5.3 Sex-specific diagnosed incident cases of CRC
4.5.4 Diagnosed incident cases of CRC by AJCC stage at diagnosis
4.5.5 Diagnosed incident cases of CRC by recurrence of stages I-III into stage IV disease
4.5.6 Diagnosed incident cases of CRC by molecular markers
4.5.7 Five-year diagnosed prevalent cases of CRC
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

*5 Disease Management*
5.1 Diagnosis and Treatment Overview
5.2 KOL insights on disease management
5.2.1 US-specific KOL insights on disease management
5.2.2 5EU-specific KOL insights on disease management
5.2.3 Japan-specific KOL insights on disease management
5.2.4 China-specific KOL insights on disease management

*6 Current Treatment Options*
6.1 Overview

*7 Unmet Needs and Opportunity Assessment*
7.1 Overview
7.2 Improving treatments for patients with KRAS/NRAS mutations
7.3 Improving treatment options in precision medicine
7.4 Overcoming resistance to EGFR- and VEGF-targeted therapies
7.5 Reduced age for routine disease screening

*8 R&D Strategies*
8.1 Overview of R&D strategies
8.1.1 Targeting MSS patients with immunotherapy
8.1.2 Combination Therapies
8.2 Clinical trials design
8.2.1 Increasing adoption of secondary quality of life endpoints
8.2.2 Increasing adoption of surrogate endpoints

*9 Pipeline Assessment*
9.1 Overview
9.2 Promising drugs in clinical development

*10 Pipeline Valuation Analysis*
10.1 Overview
10.2 Competitive assessment

*11 Current and Future Players*
11.1 Overview
11.2 Deal-making trends

*12 Market Outlook*
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.4 Japan
12.5 China

*A selection of companies mentioned in this report includes*

· Amgen
· Bayer
· Bristol Myers Squibb
· Chia Tai Tianqing Pharmaceutical Group
· Eli Lilly
· Exelixis
· Genentech
· GenFleet Therapeutics
· Gritstone bio
· GSK
· Merck
· Novartis
· Pfizer
· Qilu Pharmaceutical
· Roche
· Sanofi
· Shanghai Henlius Biotech
· SUNHO Biologics
· Takeda Pharmaceuticals
· Tracon Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/yogotu

*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900